Clinical Stage Quality & Compliance

Scaling Your Quality System for Clinical Success

As your programme advances into clinical development, expectations become more stringent, timelines tighter, and regulatory scrutiny significantly higher. BioCellGene supports your transition with phase-appropriate, inspection-ready quality and GMP strategies — ensuring your systems evolve in step with your clinical milestones.

We help you move from foundational quality to robust, defensible, and audit-ready operations — without over-engineering or slowing development.

Why Clinical Stage Quality Matters

Many organisations underestimate the shift required when entering clinical phases, leading to:

• Gaps between development practices and GMP expectations

• Incomplete IND/CTA supporting documentation

• Weak validation or qualification strategies

• Vendor and supply chain risks

• Increased regulatory questions or delays

• Inspection findings impacting trial timelines

At this stage, quality is no longer supportive — it becomes critical to programme progression

Our Approach

We apply a risk-based, phase-appropriate compliance model aligned with:

• FDA (IND / Phase 1 CGMP expectations)

• EMA & EU GMP (including Annex 1 where applicable)

• PIC/S GMP guidelines

• ICH Q7, Q8, Q9, Q10 frameworks

• GAMP 5 (for digital and CSV/CSA systems)

Our philosophy:

“Inspection-ready, clinically aligned — without unnecessary burden.”

What You Gain

By engaging BioCellGene during clinical stages, you achieve:

✔ Inspection-ready systems aligned with global expectations

✔ Reduced risk of IND/CTA delays or regulatory queries

✔ Structured and defendable CQV and validation approach

✔ Strong vendor and material control framework

✔ Faster, smoother progression through clinical phases

✔ Increased confidence with regulators, partners, and investors

Who This Is For

This service is ideal for:

• Companies entering Phase 1 / Phase 2 clinical trials

• ATMP, biologics, and advanced therapy developers

• CDMOs supporting clinical manufacturing

• Organisations preparing for regulatory submissions or inspections

• Teams scaling from R&D to GMP clinical operations

When to Engage

The optimal time to engage is:

• During IND / CTA preparation

• Before GMP manufacturing of clinical batches

• During facility or process scale-up

• Prior to regulatory inspections or audits

• When strengthening or remediating quality systems

Call to Action

Be Clinical-Ready. Stay Inspection-Ready.

Partner with BioCellGene to ensure your quality systems scale seamlessly with your clinical programme — supporting compliance, speed, and confidence at every milestone..

Book Your Complimentary 1-Hour Consultation